CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

NCT04369664 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

151

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Statin
DRUG: PCSK9 inhibitor
DRUG: Ezetimibe 10mg

Sponsor

NYU Langone Health